The CheckMate‐037 trial, which evaluated nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti‐CTLA‐4 treatment, noted statistically better ORR in BRAF‐wildtype group with nivolumab, but no statistical difference in the BRAFV600 mutant patients.30 Here, CTLA4 is linked to melanoma.